For all investor queries, please contact info@vasomune.com.
Latest News
Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy
Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy AV-001 was Safe and Well-Tolerated in Healthy Volunteers Vasomune plans to initiate
March 25, 2021
No Comments
Vasomune is Pleased to Announce the Government of Canada’s Investment in AV-001 Targeting COVID-19
Vasomune is very pleased to announce that the company has received a substantial investment on behalf of the Government of Canada through the National Research
March 17, 2021
No Comments
Vasomune Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment
First subjects have been dosed in Phase 1 study of AV-001, a novel first-in-class therapeutic Should the Phase 1 results show AV-001 is safe and
December 17, 2020
No Comments
Vasomune Announces FDA Allowance of IND Application for AV-001 for the Treatment of Hospitalized Patients with COVID-19
TORONTO, Ontario – (Business Wire) – November 12, 2020 – Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the U.S. Food and Drug Administration
November 12, 2020
No Comments